Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.40
- Piotroski Score 3.00
- Grade Buy
- Symbol (RXRX)
- Company Recursion Pharmaceuticals, Inc.
- Price $6.25
- Changes Percentage (-1.13%)
- Change -$0.07
- Day Low $6.18
- Day High $6.40
- Year High $15.74
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $12.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.63
- Trailing P/E Ratio -5.22
- Forward P/E Ratio -5.22
- P/E Growth -5.22
- Net Income $-328,066,000
Income Statement
Quarterly
Annual
Latest News of RXRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a mid-sized biotech company in pre-commercial stages, focusing on developing treatments for various ailments. It partners with AI drug discovery firm E...
By Yahoo! Finance | 2 days ago -
Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies
Recursion Pharmaceuticals Inc. is a leading biotech company utilizing AI for drug discovery, attracting investments and partnerships. Despite its growth potential, it ranks 6th among the best medical ...
By Yahoo! Finance | 1 week ago -
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc utilizes AI to speed up drug discovery. Blake Borgeson sold 350,970 shares, part of a trend with 73 insider sells and no buys. With a market cap of $1.80 billion, the sto...
By Yahoo! Finance | 2 months ago
